Benzinga - by Avi Kapoor, Benzinga Staff Writer.
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting our Analyst Stock Ratings page. Traders can sort through Benzinga's extensive database of analyst ratings, including by analyst accuracy .
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
Organon & Co. (NYSE: OGN)
- Dividend Yield: 6.13%
- Piper Sandler analyst David Amsellem maintained an Overweight rating and cut the price target from $32 to $22 on Nov. 22, 2023. This analyst has an accuracy rate of 69%.
- Morgan Stanley analyst Terence Flynn maintained an Equal-Weight rating and cut the price target from $27 to $22 on Oct. 11, 2023. This analyst has an accuracy rate of 66%.
- Recent News: On Feb. 15, Organon reported better than expected fourth-quarter earnings and issued 2024 guidance.
- Dividend Yield: 3.22%
- Oppenheimer analyst Steven Lichtman maintained a Perform rating and raised the price target from $89 to $92 on Feb. 21, 2024. This analyst has an accuracy rate of 71%.
- Truist Securities analyst Richard Newitter maintained a Hold rating and boosted the price target from $87 to $90 on Feb. 21, 2024. This analyst has an accuracy rate of 73%.
- Recent News: On March 7, Medtronic’s Neurosurgery unit said it is recalling the Duet External Drainage and Monitoring System (EDMS) catheter tubing due to a potential for the catheter disconnection from the patient line stopcock connectors.
- Dividend Yield: 3.25%
- RBC Capital analyst Gregory Renza maintained an Outperform rating and raised the price target from $303 to $329 on Feb. 7, 2024. This analyst has an accuracy rate of 70%.
- Oppenheimer analyst Jay Olson reiterated an Outperform rating with a price target of $350 on Feb. 1, 2024. This analyst has an accuracy rate of 77%.
- Recent News: Amgen announced new, 52-week results from the Phase 3 sprout study of Otezla (Apremilast) in children and adolescents aged 6 to 17 years with moderate to severe plaque psoriasis.
Read More: Dollar Tree, Williams-Sonoma And 3 Stocks To Watch Heading Into Wednesday
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.